Please wait while the formulary information is being retrieved.
Drug overview for POLYMYXIN B SULFATE (polymyxin b sulfate):
Generic name: POLYMYXIN B SULFATE
Drug class: Polymyxins
Therapeutic class: Anti-Infective Agents
Polymyxin B is a polymyxin antibiotic that is structurally and Polymyxin B is a polymyxin antibiotic. pharmacologically related to colistin.
Polymyxin B sulfate is used for the treatment of serious infections, including infections of the urinary tract, meninges, or bloodstream, caused by susceptible gram-negative bacteria (e.g., Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Klebsiella pneumoniae, Haemophilus influenzae). The drug also is used in the treatment of respiratory tract infections+ caused by susceptible gram-negative bacteria (e.g., Ps. aeruginosa, Acinetobacter baumannii+). Although other less toxic anti-infectives (e.g., fluoroquinolones, aminoglycosides, third generation cephalosporins, extended-spectrum penicillins, carbapenems) usually are the drugs of choice for most gram-negative bacterial infections, polymyxin B may be indicated when these drugs are ineffective or contraindicated, especially for serious infections caused by multidrug-resistant Ps.
aeruginosa or A. baumannii.
Generic name: POLYMYXIN B SULFATE
Drug class: Polymyxins
Therapeutic class: Anti-Infective Agents
Polymyxin B is a polymyxin antibiotic that is structurally and Polymyxin B is a polymyxin antibiotic. pharmacologically related to colistin.
Polymyxin B sulfate is used for the treatment of serious infections, including infections of the urinary tract, meninges, or bloodstream, caused by susceptible gram-negative bacteria (e.g., Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Klebsiella pneumoniae, Haemophilus influenzae). The drug also is used in the treatment of respiratory tract infections+ caused by susceptible gram-negative bacteria (e.g., Ps. aeruginosa, Acinetobacter baumannii+). Although other less toxic anti-infectives (e.g., fluoroquinolones, aminoglycosides, third generation cephalosporins, extended-spectrum penicillins, carbapenems) usually are the drugs of choice for most gram-negative bacterial infections, polymyxin B may be indicated when these drugs are ineffective or contraindicated, especially for serious infections caused by multidrug-resistant Ps.
aeruginosa or A. baumannii.
DRUG IMAGES
No Image Available
The following indications for POLYMYXIN B SULFATE (polymyxin b sulfate) have been approved by the FDA:
Indications:
Bacterial sepsis
Bacterial urinary tract infection
H. influenzae meningitis
Professional Synonyms:
Bacteremia with sepsis
Bacterial septicemia
H. flu meningitis
Haemophilus influenzae meningitis
Influenzae Bacillus meningitis
Meningitis due to Haemophilus influenzae
Meningitis due to Hemophilus influenzae
Pfeiffer's Bacillus meningitis
Indications:
Bacterial sepsis
Bacterial urinary tract infection
H. influenzae meningitis
Professional Synonyms:
Bacteremia with sepsis
Bacterial septicemia
H. flu meningitis
Haemophilus influenzae meningitis
Influenzae Bacillus meningitis
Meningitis due to Haemophilus influenzae
Meningitis due to Hemophilus influenzae
Pfeiffer's Bacillus meningitis
The following dosing information is available for POLYMYXIN B SULFATE (polymyxin b sulfate):
Potency and dosage of polymyxin B sulfate are expressed in terms of polymyxin B activity (units of polymyxin B).
Dosage of polymyxin B sulfate usually is expressed in terms of polymyxin B activity (units of polymyxin B). Dosage of the drug also may be expressed as mg of polymyxin B base. Each mg of polymyxin B is equivalent to 10,000 units of polymyxin B.
Dosage of polymyxin B should be decreased in patients with renal impairment. Serum polymyxin B concentrations should be monitored and IV or IM dosage adjusted to maintain desired serum concentrations of the drug.
Various dosage regimens have been recommended for use of polymyxin B in patients with renal impairment; however, these regimens are not well established and are not based on pharmacokinetic data from patients with renal impairment.
It has been recommended that patients with creatinine clearances of 30-80 mL/minute receive an IV loading dose of polymyxin B of 2.5 mg/kg on the first day of treatment followed by 1-1.5 mg/kg daily and that those with creatinine clearances less than 25-30 mL/minute receive these doses once every 2-3 days.
For anuric patients, some clinicians have recommended an IV loading dose of 2.5 mg/kg followed by 1-1.5 mg/kg given once every 5-7 days.
Alternatively, it has been suggested that patients with creatinine clearances greater than 20 mL/minute receive 75-100% of the usual daily dose in 2 divided doses every 12 hours, those with creatinine clearances of 5-20 mL/minute receive 50% of the usual daily dose in 2 divided doses every 12 hours, and those with creatinine clearances less than 5 mL/minute receive 30% of the usual daily dose every 12-18 hours. Some clinicians have used 75% of the usual daily dose in those with creatinine clearances 20-50 mL/minute and 33% of the usual daily dose in those with creatinine clearances less than 20 mL/minute.
Dosage of polymyxin B sulfate usually is expressed in terms of polymyxin B activity (units of polymyxin B). Dosage of the drug also may be expressed as mg of polymyxin B base. Each mg of polymyxin B is equivalent to 10,000 units of polymyxin B.
Dosage of polymyxin B should be decreased in patients with renal impairment. Serum polymyxin B concentrations should be monitored and IV or IM dosage adjusted to maintain desired serum concentrations of the drug.
Various dosage regimens have been recommended for use of polymyxin B in patients with renal impairment; however, these regimens are not well established and are not based on pharmacokinetic data from patients with renal impairment.
It has been recommended that patients with creatinine clearances of 30-80 mL/minute receive an IV loading dose of polymyxin B of 2.5 mg/kg on the first day of treatment followed by 1-1.5 mg/kg daily and that those with creatinine clearances less than 25-30 mL/minute receive these doses once every 2-3 days.
For anuric patients, some clinicians have recommended an IV loading dose of 2.5 mg/kg followed by 1-1.5 mg/kg given once every 5-7 days.
Alternatively, it has been suggested that patients with creatinine clearances greater than 20 mL/minute receive 75-100% of the usual daily dose in 2 divided doses every 12 hours, those with creatinine clearances of 5-20 mL/minute receive 50% of the usual daily dose in 2 divided doses every 12 hours, and those with creatinine clearances less than 5 mL/minute receive 30% of the usual daily dose every 12-18 hours. Some clinicians have used 75% of the usual daily dose in those with creatinine clearances 20-50 mL/minute and 33% of the usual daily dose in those with creatinine clearances less than 20 mL/minute.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for POLYMYXIN B SULFATE (polymyxin b sulfate):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 3 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Anesthetics/Aminoglycosides SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The neuromuscular blocking activity of aminoglycosides results from a decreased sensitivity at the postjunctional membrane and interfere with transmitter release.(1) These actions produce a synergistic effect with anesthetic agents that produce neuromuscular blockade.(2,3) Some anesthetics cause renal failure due to release of fluoride ion. Aminoglycosides cause nephrotoxicity when high doses are given.(4,5) CLINICAL EFFECTS: Increased neuromuscular blockade activity, profound sedation, respiratory depression, coma, and/or death. Circulatory collapse may also occur secondary to the neuromuscular blockade.(6-10) Decreased urinary output and increased BUN and serum creatinine may indicate renal impairment. PREDISPOSING FACTORS: Patients in respiratory distress, history of renal impairment and high doses of aminoglycosides and anesthetics. PATIENT MANAGEMENT: Monitor neuromuscular blockade with train-of-four stimulus. Monitor vital signs, and respiratory rate. Intravenous neostigmine (0.2 to 2.5 mg), calcium (1 G), and possibly sodium bicarbonate (dose not reported) may be beneficial in reversal of neuromuscular blockade and respiratory depression.(6-10) Supportive care and ventilation should be utilized until the neuromuscular blockade is resolved. Volume replacement may be necessary for circulatory collapse.(6-10) Monitor BUN, serum creatinine, and urinary output and adjust aminoglycoside and anesthetic doses according to renal function. DISCUSSION: Aminoglycosides including kanamycin(6,11), streptomycin(6,13), amikacin(13), gentamicin(7,13-15), neomycin, and tobramycin(13) have been documented to have neuromuscular blocking activity. There is no documentation with netilmicin and paromomycin, though it is assumed that they produce the same effects as the other members of this class. Neomycin has been shown to interact with cyclopropane(8,9), halothane(6), methoxyflurane(6), and nitrous oxide(6). Enflurane, ethylene, and isoflurane share similar properties to the previous inhalation anesthetics and would likely interact with neomycin. Kanamycin(6,11) and streptomycin (6,12) are known to interact with ether. Gentamicin has been reported to potentiate atracurium.(16) Therefore it is hypothesized that all aminoglycosides interact with the inhaled anesthetics. One study evaluating gentamicin and halothane in animals did not exhibit a decrease in muscle strength.(17) Aminoglycosides have been proven to be nephrotoxic at high doses. Anesthetics containing fluoride also produce renal dysfunction. Nephrotoxicity occurred more often when gentamicin or tobramycin were given with enflurane than when enflurane was given alone or in patients who received nitrous oxide and opioid anesthesia.(4) |
DESFLURANE, FORANE, ISOFLURANE, SUPRANE, TERRELL |
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
| Selected Nephrotoxic Agents/Polymyxin B SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Polymyxin B can cause nephrotoxicity with a slight degree of tubular damage. Concurrent administration of other nephrotoxic agents may result in an increased risk of nephrotoxicity.(1) CLINICAL EFFECTS: Concurrent use of polymyxin B with other nephrotoxic agents may result in additive nephrotoxic effects. Polymyxin B nephrotoxicity is characterized by albuminuria, cellular casts, azotemia, diminished urine output, elevated BUN and rising blood levels usually after about 4 days of therapy.(1,2) PREDISPOSING FACTORS: Factors predisposing to nephrotoxicity include higher cumulative doses and longer duration of therapy of polymyxin B and exposure to multiple nephrotoxins.(2) PATIENT MANAGEMENT: Concurrent or sequential use of potentially nephrotoxic agents with polymyxin B should be avoided. If concurrent use is necessary, it should be undertaken with great caution. Check renal function at baseline and monitor renal function and polymyxin B blood levels frequently during therapy.(1) DISCUSSION: Polymyxin B is associated with high rates of nephrotoxicity. Concurrent use with other nephrotoxins may increase the risk of nephrotoxicity. |
AMIKACIN SULFATE, ARIKAYCE, BACITRACIN, BACITRACIN MICRONIZED, BACITRACIN ZINC, BETHKIS, COLISTIMETHATE, COLISTIMETHATE SODIUM, COLY-MYCIN M PARENTERAL, GENTAMICIN SULFATE, GENTAMICIN SULFATE IN NS, GENTAMICIN-SODIUM CITRATE, KANAMYCIN SULFATE, KITABIS PAK, NEOMYCIN SULFATE, STREPTOMYCIN SULFATE, TOBI, TOBI PODHALER, TOBRAMYCIN, TOBRAMYCIN SULFATE |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Neuromuscular Blocking Agents/Polypeptide Antibiotics SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Synergistic pharmacologic activity. Polymyxin B affects neuromuscular transmission by blocking acetylcholine receptors. Its action is thus post-synaptic and the neuromuscular block has no antagonists. Polymyxin B causes neostigmine resistance to d-tubocurarine blockade and calcium resistance to the blockade evoked by aminoglycoside antibiotics (1,2,3,4). A pre-synaptic mechanism may also be involved with decreased release of acetylcholine. CLINICAL EFFECTS: May see an increase in the neuromuscular blocking effects, including profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If it is necessary to administer these drugs concurrently, do so with extreme caution. Monitor neuromuscular function and adjust the dose of the neuromuscular blocking agent accordingly. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: Concomitant administration of polypeptide antibiotics and neuromuscular blocking agents has been shown to produce synergism of the effects on skeletal muscles. Concurrent administration of these drugs has been associated with prolonged respiratory depression, respiratory paralysis, and apnea. This interaction has been documented with colistimethate, polymyxin B, bacitracin, and vancomycin. |
ANECTINE, ATRACURIUM BESYLATE, BOTOX, BOTOX COSMETIC, CISATRACURIUM BESYLATE, DAXXIFY, DYSPORT, JEUVEAU, MYOBLOC, NIMBEX, QUELICIN, ROCURONIUM BROMIDE, SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE-NACL, VECURONIUM BROMIDE, VECURONIUM BROMIDE-WATER, XEOMIN |
The following contraindication information is available for POLYMYXIN B SULFATE (polymyxin b sulfate):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Oliguria |
| Pregnancy |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Clostridioides difficile infection |
| Myasthenia gravis |
| Systemic mastocytosis |
There are 0 moderate contraindications.
The following adverse reaction information is available for POLYMYXIN B SULFATE (polymyxin b sulfate):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 5 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
CNS toxicity Fever Nephrotoxicity Neuromuscular blockade Skin rash |
There are 0 less severe adverse reactions.
The following precautions are available for POLYMYXIN B SULFATE (polymyxin b sulfate):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Animal reproduction studies have not been performed with polymyxin B sulfate. It is not known whether ophthalmic preparations containing polymyxin B sulfate can cause fetal harm when administered to pregnant women. Fixed-combination ophthalmic preparations of polymyxin B sulfate and bacitracin zinc or polymyxin B sulfate, neomycin sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed.
Because trimethoprim may interfere with folic acid metabolism, fixed-combination ophthalmic preparations containing polymyxin B sulfate and trimethoprim sulfate should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, other anti-infectives (i.e., neomycin sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus.
The safety of polymyxin B sulfate in pregnant women has not been established. Some clinicians state that polymyxin B should not be used during pregnancy, except in rare situations when other appropriate anti-infectives cannot be used. If use of the fixed-combination solution for irrigation containing polymyxin B sulfate and neomycin sulfate is being considered for a pregnant woman, the woman should be informed of the potential hazard to the fetus.
Aminoglycosides cross the placenta and there have been reports of complete, irreversible, bilateral congenital deafness in children whose mothers received an aminoglycoside (i.e., streptomycin) during pregnancy.
Because trimethoprim may interfere with folic acid metabolism, fixed-combination ophthalmic preparations containing polymyxin B sulfate and trimethoprim sulfate should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, other anti-infectives (i.e., neomycin sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus.
The safety of polymyxin B sulfate in pregnant women has not been established. Some clinicians state that polymyxin B should not be used during pregnancy, except in rare situations when other appropriate anti-infectives cannot be used. If use of the fixed-combination solution for irrigation containing polymyxin B sulfate and neomycin sulfate is being considered for a pregnant woman, the woman should be informed of the potential hazard to the fetus.
Aminoglycosides cross the placenta and there have been reports of complete, irreversible, bilateral congenital deafness in children whose mothers received an aminoglycoside (i.e., streptomycin) during pregnancy.
Fixed-combination ophthalmic preparations containing polymyxin B sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, neomycin sulfate, trimethoprim sulfate) should be used with caution in nursing women. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, and dexamethasone should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for POLYMYXIN B SULFATE (polymyxin b sulfate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for POLYMYXIN B SULFATE (polymyxin b sulfate)'s list of indications:
| Bacterial sepsis | |
| A02.1 | Salmonella sepsis |
| A20.7 | Septicemic plague |
| A22.7 | Anthrax sepsis |
| A26.7 | Erysipelothrix sepsis |
| A32.7 | Listerial sepsis |
| A40 | Streptococcal sepsis |
| A40.0 | Sepsis due to streptococcus, group A |
| A40.1 | Sepsis due to streptococcus, group B |
| A40.3 | Sepsis due to streptococcus pneumoniae |
| A40.8 | Other streptococcal sepsis |
| A40.9 | Streptococcal sepsis, unspecified |
| A41 | Other sepsis |
| A41.0 | Sepsis due to staphylococcus aureus |
| A41.01 | Sepsis due to methicillin susceptible staphylococcus aureus |
| A41.02 | Sepsis due to methicillin resistant staphylococcus aureus |
| A41.1 | Sepsis due to other specified staphylococcus |
| A41.2 | Sepsis due to unspecified staphylococcus |
| A41.3 | Sepsis due to hemophilus influenzae |
| A41.4 | Sepsis due to anaerobes |
| A41.5 | Sepsis due to other gram-negative organisms |
| A41.50 | Gram-negative sepsis, unspecified |
| A41.51 | Sepsis due to escherichia coli [e. coli] |
| A41.52 | Sepsis due to pseudomonas |
| A41.53 | Sepsis due to serratia |
| A41.54 | Sepsis due to acinetobacter baumannii |
| A41.59 | Other gram-negative sepsis |
| A41.8 | Other specified sepsis |
| A41.81 | Sepsis due to enterococcus |
| A41.89 | Other specified sepsis |
| A41.9 | Sepsis, unspecified organism |
| A42.7 | Actinomycotic sepsis |
| A54.86 | Gonococcal sepsis |
| O03.37 | Sepsis following incomplete spontaneous abortion |
| O08.82 | Sepsis following ectopic and molar pregnancy |
| O85 | Puerperal sepsis |
| O86.04 | Sepsis following an obstetrical procedure |
| P36 | Bacterial sepsis of newborn |
| P36.0 | Sepsis of newborn due to streptococcus, group B |
| P36.1 | Sepsis of newborn due to other and unspecified streptococci |
| P36.10 | Sepsis of newborn due to unspecified streptococci |
| P36.19 | Sepsis of newborn due to other streptococci |
| P36.2 | Sepsis of newborn due to staphylococcus aureus |
| P36.3 | Sepsis of newborn due to other and unspecified staphylococci |
| P36.30 | Sepsis of newborn due to unspecified staphylococci |
| P36.39 | Sepsis of newborn due to other staphylococci |
| P36.4 | Sepsis of newborn due to escherichia coli |
| P36.5 | Sepsis of newborn due to anaerobes |
| P36.8 | Other bacterial sepsis of newborn |
| P36.9 | Bacterial sepsis of newborn, unspecified |
| R65.2 | Severe sepsis |
| T81.12 | Postprocedural septic shock |
| T81.12xA | Postprocedural septic shock, initial encounter |
| T81.44 | Sepsis following a procedure |
| T81.44xA | Sepsis following a procedure, initial encounter |
| Bacterial urinary tract infection | |
| N30.0 | Acute cystitis |
| N30.00 | Acute cystitis without hematuria |
| N30.01 | Acute cystitis with hematuria |
| N30.9 | Cystitis, unspecified |
| N30.90 | Cystitis, unspecified without hematuria |
| N30.91 | Cystitis, unspecified with hematuria |
| N39.0 | Urinary tract infection, site not specified |
| O23.0 | Infections of kidney in pregnancy |
| O23.00 | Infections of kidney in pregnancy, unspecified trimester |
| O23.01 | Infections of kidney in pregnancy, first trimester |
| O23.02 | Infections of kidney in pregnancy, second trimester |
| O23.03 | Infections of kidney in pregnancy, third trimester |
| O23.1 | Infections of bladder in pregnancy |
| O23.10 | Infections of bladder in pregnancy, unspecified trimester |
| O23.11 | Infections of bladder in pregnancy, first trimester |
| O23.12 | Infections of bladder in pregnancy, second trimester |
| O23.13 | Infections of bladder in pregnancy, third trimester |
| O23.2 | Infections of urethra in pregnancy |
| O23.20 | Infections of urethra in pregnancy, unspecified trimester |
| O23.21 | Infections of urethra in pregnancy, first trimester |
| O23.22 | Infections of urethra in pregnancy, second trimester |
| O23.23 | Infections of urethra in pregnancy, third trimester |
| O23.3 | Infections of other parts of urinary tract in pregnancy |
| O23.30 | Infections of other parts of urinary tract in pregnancy, unspecified trimester |
| O23.31 | Infections of other parts of urinary tract in pregnancy, first trimester |
| O23.32 | Infections of other parts of urinary tract in pregnancy, second trimester |
| O23.33 | Infections of other parts of urinary tract in pregnancy, third trimester |
| O23.4 | Unspecified infection of urinary tract in pregnancy |
| O23.40 | Unspecified infection of urinary tract in pregnancy, unspecified trimester |
| O23.41 | Unspecified infection of urinary tract in pregnancy, first trimester |
| O23.42 | Unspecified infection of urinary tract in pregnancy, second trimester |
| O23.43 | Unspecified infection of urinary tract in pregnancy, third trimester |
| O23.90 | Unspecified genitourinary tract infection in pregnancy, unspecified trimester |
| O23.91 | Unspecified genitourinary tract infection in pregnancy, first trimester |
| O23.92 | Unspecified genitourinary tract infection in pregnancy, second trimester |
| O23.93 | Unspecified genitourinary tract infection in pregnancy, third trimester |
| P39.3 | Neonatal urinary tract infection |
| T83 | Complications of genitourinary prosthetic devices, implants and grafts |
| T83.5 | Infection and inflammatory reaction due to prosthetic device, implant and graft in urinary system |
| T83.51 | Infection and inflammatory reaction due to urinary catheter |
| T83.59 | Infection and inflammatory reaction due to prosthetic device, implant and graft in urinary system |
| T83.6 | Infection and inflammatory reaction due to prosthetic device, implant and graft in genital tract |
| H. influenzae meningitis | |
| G00.0 | Hemophilus meningitis |
Formulary Reference Tool